within Pharmacolibrary.Drugs.ATC.R;

model R01AD05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0014,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AD05</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Budesonide is a synthetic corticosteroid with potent glucocorticoid activity and low systemic bioavailability due to high first-pass metabolism. It is primarily used in the prophylaxis and treatment of allergic rhinitis, as well as in the management of asthma and other inflammatory airway disorders. Budesonide via nasal route (ATC code R01AD05) is an approved and commonly used drug today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single intranasal administration.</p><h4>References</h4><ol><li><p>Li, X, et al., &amp; Guo, S (2021). A sensitive and high-throughput LC-ESI-MS/MS method to detect budesonide in human plasma: application to an evaluation of pharmacokinetics of budesonide intranasal formulations with and without charcoal-block in healthy volunteers. <i>Drug development and industrial pharmacy</i> 47(2) 329–336. DOI:<a href=\"https://doi.org/10.1080/03639045.2021.1879842\">10.1080/03639045.2021.1879842</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33523774/\">https://pubmed.ncbi.nlm.nih.gov/33523774</a></p></li><li><p>Szefler, SJ (2001). Pharmacokinetics of intranasal corticosteroids. <i>The Journal of allergy and clinical immunology</i> 108(1 Suppl) S26–S31. DOI:<a href=\"https://doi.org/10.1067/mai.2001.115563\">10.1067/mai.2001.115563</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11449203/\">https://pubmed.ncbi.nlm.nih.gov/11449203</a></p></li><li><p>Wellington, K, &amp; Jarvis, B (2001). Cetirizine/pseudoephedrine. <i>Drugs</i> 61(15) 2231–2242. DOI:<a href=\"https://doi.org/10.2165/00003495-200161150-00009\">10.2165/00003495-200161150-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11772135/\">https://pubmed.ncbi.nlm.nih.gov/11772135</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AD05;
